drugset
drugset / Trial / NCT07623915

A Clinical Study to Evaluate the Efficacy and Safety of Bempedoic Acid

NCT07623915 ↗

Phase 3 Not yet recruiting 222 enrolled CSPC Ouyi Pharmaceutical Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

This trial is a multicenter randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of Bempedoic Acid Tablets in patients with hyperlipidemia not adequately controlled by Statins.

Timeline

Start
2026-06-12
Primary completion
2027-06-30
Completion
2027-08-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Bempedoic acid Small molecule 180 mg Oral

Indications

hyperlipoproteinemia